Novartis Remibrutinib Significantly Reduces Relapse Rates In Phase III RMS Trials
Novartis Remibrutinib Significantly Reduces Relapse Rates In Phase III RMS Trials
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novartis remibrutinib trial data in Phase III RMS
TradingView reports Phase III RMS results for Novartis remibrutinib, an oral BTK inhibitor, citing reduced relapse rates and a favorable safety profile.